Schizophrenia | Disease Landscape & Forecast | G7 | 2021
The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for the late-phase and recently approved therapies not specifically targeting schizophrenia subpopulations with high unmet need—including new oral atypical antipsychotics (e.g., Alkermes’s Lybalvi), new LAIs (e.g., Janssen’s paliperidone six-month depot, Teva’s TV-46000), and other agents with novel mechanisms of action (e.g., Sunovion / Sumitomo Dainippon Pharma’s ulotaront [SEP-363856], Karuna’s KarXT). Although the potential of therapies in development to treat the negative symptoms of schizophrenia or the cognitive impairment associated with schizophrenia (CIAS) remains to be seen in late-phase studies, some agents had promising results in mid-phase clinical studies and could earn blockbuster sales, such as Acadia Pharmaceuticals’ pimavanserin and Boehringer Ingelheim’s BI 425809.
Questions Answered
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What percentage of diagnosed lifetime prevalent schizophrenia patients receive drug treatment? How large are the schizophrenia subpopulations with negative symptoms or cognitive impairment?
- What are the greatest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs?
- How will novel emerging therapies be positioned in the schizophrenia treatment algorithm?
Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement: Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, EU5, Japan.
Primary research: 28 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; drug-treated prevalence of schizophrenia by country.
Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2030, segmented by brands / generics.
Emerging therapies: Phase III / PR: 10 drugs. Coverage of select Phase II and Phase I products.
